Last reviewed · How we verify
HT-102
At a glance
| Generic name | HT-102 |
|---|---|
| Sponsor | Suzhou HepaThera Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection (PHASE2)
- A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection (PHASE1, PHASE2)
- Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B Virus (NA)
- Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HT-102 CI brief — competitive landscape report
- HT-102 updates RSS · CI watch RSS
- Suzhou HepaThera Biotech Co., Ltd. portfolio CI